Cancer research that once involved years of painstaking work can now happen in months with a novel technique for studying cancer-related genes. The results reveal how combinations of mutations influence tumor growth.
April 4, 2018 - By Ker Than
Stanford scientists have found a way to modify pairs of cancer-related genes in the lungs of mice and then precisely track individual cells of the resulting tumor — a technique that could dramatically speed up cancer research and drug development.
The work could finally allow scientists to mimic and then study the genetic diversity of cells found in tumors outside the lab.
“Human cancers don’t have only one tumor-suppression mutation — they have combinations. The question is, how do different mutated genes cooperate or not cooperate with one another?” said Monte Winslow, PhD, assistant professor of genetics and of pathology at the School of Medicine.
Just a few years ago, such a mapping study would have been a monumental, years-long effort. It would have required breeding several lineages of genetically modified mice, each with a different pair of inactivated tumor-suppressor genes. To explore all of the possible combinations, hundreds or thousands of mice would have been needed.
In contrast, Winslow and his colleagues conducted their experiments, which involved fewer than two dozen mice, in just a few months. “We’ve analyzed more genotypes of lung cancer tumors than the whole field has in 15 years,” Winslow said.
A paper describing the technique was published online April 2 in Nature Genetics. Senior authorship is shared by Winslow and Dmitri Petrov, PhD, professor of biology and the Michelle and Kevin Douglas Professor in the School of Humanities and Sciences. Postdoctoral scholar Christopher McFarland, PhD, and former graduate student Zoë Rogers, PhD, are the lead authors.
A wild idea
The team achieved their results using CRISPR-Cas9 — a powerful gene-editing tool that can easily replace, modify or delete genetic sequences inside organisms — to create multiple, genetically distinct tumors in the lungs of individual animals. “We can induce thousands of clonal tumors in a single mouse,” Winslow said.
However, in order to draw useful conclusions about the combinatory effects of different gene mutations, the scientists needed a precise way to label and track the growth of different tumors. Here again, conventional techniques, which involved trying to excise and compare the sizes of individual tumors, would have been insufficient.
“Not only was it extremely slow, but how do you pluck out a tumor that’s weirdly shaped, or one that’s stuck to another tumor?” said study co-author Ian Winters, a graduate student in Winslow’s lab. “We needed a better way to quantify tumor sizes.”
The solution came from an unexpected source. Petrov, an evolutionary biologist, had been working with Stanford colleagues to develop DNA barcoding as a way of investigating rapid evolution in yeast. When Petrov learned about the experiments in Winslow’s group, he thought that the technique might also work in mice.
“Dmitri’s the sort of guy who has a lot of wild ideas, and at first we didn’t think that what he was suggesting was possible,” Winslow said. “But after we thought about it for a couple of days, we realized that, well, actually, maybe we can do that.”
Petrov’s idea was to attach short, unique sequences of DNA to individual tumor cells inside mice lungs. Each sequence functions as a heritable genetic barcode, and as each cancer seed cell divides, growing into a tumor, the number of barcodes also multiplies.
Now, instead of having to painstakingly cut out individual tumors, the scientists could take an entire cancerous lung, grind it up, and then use high-throughput DNA sequencing and computational analysis to precisely determine how big a tumor was by counting how often its barcodes popped up. By tallying different barcodes, the scientists could compare tumor sizes much more quantitatively than was previously possible.
“This is 10 steps forward in our ability to model human cancer,” Petrov said. “We can now generate a very large number of tumors with specific genetic signatures in the same mouse and follow their growth individually at scale and with high precision. The previous methods were both orders of magnitude slower and much less quantitative.”
The combination of CRISPR-Cas9 and DNA barcoding could allow scientists to replicate in the lab the kind of genetic diversity observed in cancer patients. “It gets around this fear of the complexity of cancer,” Winters said. “We’ve known for decades that human tumors are extremely complex and different from patient to patient, but how do you actually recreate that so you can study it? It’s not by doing it one at a time. Now, we can model 30 different genetic variations of a cancer simultaneously.”
One striking finding from the team’s mapping study is that many tumor-suppressor genes are context-dependent — that is, they only affect cancer growth in the presence or absence of another gene. “We are now in a good position to understand how key cancer drivers interact with each other, and why tumors with the same mutations sometimes grow to be very large and sometimes not,” McFarland said.
This is 10 steps forward in our ability to model human cancer.
The team’s hybrid technique could also prove valuable for cancer-drug testing. Pharmaceutical companies could test a drug on thousands of tumor variations simultaneously to see which ones respond to treatment and, just as importantly, which ones don’t.
“We can help understand why targeted therapies and immunotherapies sometimes work amazingly well in patients and sometimes fail,” Petrov said. “We hypothesize that the genetic identity of tumors might be partially responsible, and we finally have a good way to test this.”
Petrov is an affiliate of the Stanford Woods Institute for the Environment. Winslow is a member of the Stanford Cancer Institute and the Stanford Neurosciences Institute. Both are members of Stanford Bio-X.
Other Stanford co-authors are postdoctoral scholar Jose Seoane, PhD; former postdoctoral scholar Jennifer Brady, PhD; and Christina Curtis, PhD, assistant professor of oncology and of genetics.
A former undergraduate student at the Massachusetts Institute of Technology also contributed to the work.
The study was supported by the National Science Foundation, the National Institutes of Health, Stanford Graduate Fellowships, the Stanford Cancer Systems Biology Scholars Program, Susan G. Komen and the Stanford Cancer Institute.
Stanford’s departments of Genetics, of Pathology and of Biology also supported the work.
About Stanford Medicine
Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.